![](/images/2013/post-sep.jpg)
Keytruda Global Market 2024 To Reach $31.52 Billion By 2028 At Rate Of 9.9%
The Business Research Company's Keytruda Global Market Report 2024 – Market Size, Trends, And Global Forecast 2024-2033
LONDON, GREATER LONDON, UK, August 19, 2024 /EINPresswire.com/ -- The keytruda market has experienced robust growth in recent years, expanding from $19.71 billion in 2023 to $21.60 billion in 2024 at a compound annual growth rate (CAGR) of 9.6%. The growth in the historic period can be attributed to improved patient outcomes, increased adoption of immunotherapy, research and development, improved patient compliance, and increased adoption of keytruda.
Strong Future Growth Anticipated
The keytruda market is projected to continue its strong growth, reaching $31.52 billion in 2028 at a compound annual growth rate (CAGR) of 9.9%. The growth in the forecast period can be attributed to expanding indications, emerging markets, increasing prevalence of cancer, rising healthcare expenditure, and growing demand for precision medicine.
Explore Comprehensive Insights Into The Global Keytruda Market With A Detailed Sample Report:
https://www.thebusinessresearchcompany.com/sample_request?id=16457&type=smp
Growth Driver Of The Keytruda Market
The increasing prevalence of cancer is expected to propel the growth of the keytruda market going forward. Cancer is a complex group of diseases characterized by the abnormal growth and spread of cells. The prevalence of cancer is due to genetic factors, lifestyle factors, environmental factors, and hormonal factors. Keytruda (pembrolizumab) helps in cancer treatment primarily by harnessing the body's immune system to fight cancer cells more effectively. It represents a significant advancement in cancer treatment by harnessing the power of the immune system to target and attack cancer cells, providing new hope for many patients with advanced or metastatic cancers.
Make Your Report Purchase Here And Explore The Whole Industry's Data As Well:
https://www.thebusinessresearchcompany.com/report/keytruda-global-market-report
Major Players And Market Trends
Key players in the keytruda market include Pfizer Inc., Johnson & Johnson Services Inc., Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Novartis AG, AstraZeneca PLC.
Major companies operating in keytruda market are developing innovative products such as pembrolizumab to expand treatment options. Pembrolizumab is a monoclonal antibody medication that belongs to a class of drugs known as immune checkpoint inhibitors. It is marketed under the brand name Keytruda. Pembrolizumab targets and blocks a protein called PD-1 (programmed cell death protein 1) on immune cells known as T cells.
Segments:
1) By Cancer Type: Melanoma, Lung Cancer, Head And Neck Cancer, Hodgkin Lymphoma, Stomach Cancer, Urothelial Carcinoma
2) By Payer Type: Commercial, Medicare, Medicaid
3) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies
Geographical Insights: North America Leading The Market
North America was the largest region in the keytruda market in 2023. The regions covered in the keytruda market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Keytruda Market Definition
Keytruda is a brand name for pembrolizumab, a monoclonal antibody medication used in cancer treatment. Keytruda belongs to a class of drugs known as immune checkpoint inhibitors. It works by targeting and blocking a protein called PD-1 (programmed cell death protein 1) in immune cells, which helps the immune system recognize and attack cancer cells.
Keytruda Global Market Report 2024 from The Business Research Company covers the following information:
• Market size data for the forecast period: Historical and Future
• Market analysis by region: Asia-Pacific, China, Western Europe, Eastern Europe, North America, USA, South America, Middle East and Africa.
• Market analysis by countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.
Trends, opportunities, strategies and so much more.
The Keytruda Global Market Report 2024 by The Business Research Company is the most comprehensive report that provides insights on keytruda market size, keytruda market drivers and trends, keytruda market major players, keytruda competitors' revenues, keytruda market positioning, and keytruda market growth across geographies. The keytruda market report helps you gain in-depth insights into opportunities and strategies. Companies can leverage the data in the report and tap into segments with the highest growth potential.
Browse Through More Similar Reports By The Business Research Company:
Keycaps Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/keycaps-global-market-report
Keyboards Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/keyboards-global-market-report
Automotive Smart Key Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/automotive-smart-key-global-market-report
About The Business Research Company?
The Business Research Company has published over 15000+ reports in 27 industries, spanning 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.
Global Market Model – Market Intelligence Database
The Global Market Model, The Business Research Company’s flagship product, is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets that help its users assess supply-demand gaps.
Contact Information
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Oliver Guirdham
The Business Research Company
+ +44 20 7193 0708
email us here
Visit us on social media:
Facebook
X
LinkedIn
YouTube
![](https://health.einnews.com/tracking/article.gif?aid=736468421§ion=einpresswire&a=8JsexieplNvsUdJl&i=GlGPth94jpTr0HK9)
EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.